232 related articles for article (PubMed ID: 28576443)
1. A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).
Boccia RV; Bessudo A; Agajanian R; Conkling P; Harb W; Yang H; Pinchasik D; Kimball AS; Berenson JR
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):433-437. PubMed ID: 28576443
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.
Bringhen S; D'Agostino M; De Paoli L; Montefusco V; Liberati AM; Galieni P; Grammatico S; Muccio VE; Esma F; De Angelis C; Musto P; Ballanti S; Offidani M; Petrucci MT; Gaidano G; Corradini P; Palumbo A; Sonneveld P; Boccadoro M
Leukemia; 2018 Apr; 32(4):979-985. PubMed ID: 29263440
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
[TBL] [Abstract][Full Text] [Related]
5. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
[TBL] [Abstract][Full Text] [Related]
6. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly
Bringhen S; Mina R; Petrucci MT; Gaidano G; Ballanti S; Musto P; Offidani M; Spada S; Benevolo G; Ponticelli E; Galieni P; Cavo M; Di Toritto TC; Di Raimondo F; Montefusco V; Palumbo A; Boccadoro M; Larocca A
Haematologica; 2019 Aug; 104(8):1640-1647. PubMed ID: 30733270
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Bringhen S; Petrucci MT; Larocca A; Conticello C; Rossi D; Magarotto V; Musto P; Boccadifuoco L; Offidani M; Omedé P; Gentilini F; Ciccone G; Benevolo G; Genuardi M; Montefusco V; Oliva S; Caravita T; Tacchetti P; Boccadoro M; Sonneveld P; Palumbo A
Blood; 2014 Jul; 124(1):63-9. PubMed ID: 24855212
[TBL] [Abstract][Full Text] [Related]
10. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Leleu X; Fouquet G; Richez V; Guidez S; Duhamel A; Machuron F; Karlin L; Kolb B; Tiab M; Araujo C; Meuleman N; Malfuson JV; Bourquard P; Lenain P; Roussel M; Jaccard A; Pétillon MO; Belhadj-Merzoug K; Lepeu G; Chrétien ML; Fontan J; Rodon P; Schmitt A; Offner F; Voillat L; Cereja S; Kuhnowski F; Rigaudeau S; Decaux O; Humbrecht-Kraut C; Frayfer J; Fitoussi O; Roos-Weil D; Eisenmann JC; Dorvaux V; Voog EG; Attal M; Moreau P; Avet-Loiseau H; Hulin C; Facon T
Clin Cancer Res; 2019 Jul; 25(14):4224-4230. PubMed ID: 31053600
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
Mikhael JR; Reeder CB; Libby EN; Costa LJ; Bergsagel PL; Buadi F; Mayo A; Nagi Reddy SK; Gano K; Dueck AC; Stewart AK
Br J Haematol; 2015 Apr; 169(2):219-27. PubMed ID: 25683772
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
[TBL] [Abstract][Full Text] [Related]
14. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Biran N; Siegel D; Berdeja JG; Raje N; Cornell RF; Alsina M; Kovacsovics T; Fang B; Kimball AS; Landgren O
Am J Hematol; 2019 Jul; 94(7):794-802. PubMed ID: 31021005
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Vandross A
Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Hájek R; Masszi T; Petrucci MT; Palumbo A; Rosiñol L; Nagler A; Yong KL; Oriol A; Minarik J; Pour L; Dimopoulos MA; Maisnar V; Rossi D; Kasparu H; Van Droogenbroeck J; Yehuda DB; Hardan I; Jenner M; Calbecka M; Dávid M; de la Rubia J; Drach J; Gasztonyi Z; Górnik S; Leleu X; Munder M; Offidani M; Zojer N; Rajangam K; Chang YL; San-Miguel JF; Ludwig H
Leukemia; 2017 Jan; 31(1):107-114. PubMed ID: 27416912
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
Forsberg PA; Rossi AC; Boyer A; Tegnestam L; Pearse RN; Perry A; Pekle KA; Jayabalan D; Ely S; Boussi L; Sherbenou DW; Williams C; Allan JN; Coleman M; Niesvizky R; Mark TM
Am J Hematol; 2019 May; 94(5):539-545. PubMed ID: 30740766
[TBL] [Abstract][Full Text] [Related]
20. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
